7 July 2022 - Updated Winter Dose Recommendations

Adults aged 50 to 64 years are now recommended to receive a winter booster dose of a COVID-19 vaccine.

Key changes to ATAGI advice between - July 2022 and October

2023\*

Key changes to ATAGI Adults aged 30 to 49 years can receive a winter booster dose of a COVID-19 vaccine, however the benefit for people in this age group is less certain.

The interval recommended between a recent SARS-CoV-2 infection or the first booster dose and a winter booster dose is now 3 months.

## 7 February 2023 - 2023 Booster

- ATAGI <u>recommends</u> a 2023 COVID-19 vaccine booster dose for adults in the following groups, if **their last COVID-19 vaccine dose or confirmed infection** (whichever is the most recent) was **6 months ago or longer**, and regardless of the number of prior doses received:
- \* All adults aged 65 years and over
- \* Adults aged 18-64 years who have medical comorbidities that increase their risk of severe COVID-19, or disability with significant or complex health needs

1 September 2023 - Additional Dose

ATAGI recommends that all adults aged ≥
75 years should receive an additional
2023 COVID-19 vaccine dose if 6 months
have passed since their last dose or
confirmed infection and that those 65-74
years, and those 18-64 years with severe
immunocompromise should consider an
additional 2023 COVID-19 vaccine dose.

Whole Population	Jul-22	Aug-22	Sep-22	Oct-22	Nov-22	Dec-22	Jan-23	Feb-23	Mar-23	Apr-23	May-23	Jun-23	Jul-23	Aug-23	Sep-23	Oct-23
Primary Course	22,498,610 (87.6%)	22,520,020 (87.7%)	22,534,011 (87.7%)	22,544,925 (87.8%)	22,557,036 (87.8%)	22,567,201 (87.9%)	22,578,479 (87.9%)	22,584,889 (87.9%)	22,591,766 (87.9%)	22,598,383 (88.0%)	22,607,040 (88.0%)	22,613,922 (88.0%)	22,618,614 (88.1%)	22,622,543 (88.1%)	22,625,156 (88.1%)	22,626,518 (88.1%)
Dose 3+	14,242,705 (55.4%)	14,350,756 (55.9%)	14,408,985 (56.1%)	14,446,986 (56.2%)	14,492,066 (56.4%)	14,525,081 (56.5%)	14,553,258 (56.7%)	14,573,764 (56.7%)	, , (,	14,617,261 (56.9%)	14,642,057 (57.0%)	14,660,850 (57.1%)	14,673,022 (57.1%)	14,682,666 (57.2%)	14,688,790 (57.2%)	14,691,775 (57.2%)
Dose 4+	4,077,421 (15.9%)	4,739,259 (18.4%)	4,931,245 (19.2%)	5,070,058 (19.7%)	5,326,615 (20.7%)	, , , ,	5,518,959 (21.5%)	5,575,524 (21.7%)	5,669,769 (22.1%)	5,812,513 (22.6%)	6,029,070 (23.5%)	6,169,007 (24.0%)	6,230,679 (24.3%)	6,264,313 (24.4%)	6,283,520 (24.5%)	6,292,609 (24.5%)
Dose 5+	41,595 (0.2%)	57,935 (0.2%)	66,169 (0.3%)	75,942 (0.3%)	103,229 (0.4%)	122,524 (0.5%)	134,154 (0.5%)	334,497 (1.3%)	925,019 (3.6%)	1,589,831 (6.2%)	2,309,830 (9.0%)	2,699,201 (10.5%)	2,867,172 (11.2%)	2,952,633 (11.5%)	3,003,275 (11.7%)	3,028,523 (11.8%)
Dose 6+	1,408 (0.0%)	1,715 (0.0%)	1,903 (0.0%)	2,283 (0.0%)	3,250 (0.0%)	3,937 (0.0%)	4,383 (0.0%)	8,096 (0.0%)	20,156 (0.1%)	34,732 (0.1%)	52,891 (0.2%)	65,557 (0.3%)	72,212 (0.3%)	83,453 (0.3%)	118,731 (0.5%)	150,177 (0.6%)
Primary Course	405,198 (89.3%)	405,687 (89.4%)	406,003 (89.5%)	406,240 (89.6%)	406,607 (89.6%)	406,990 (89.7%)	407,290 (89.8%)	407,429 (89.8%)	407,593 (89.9%)	407,767 (89.9%)	408,031 (90.0%)	408,266 (90.0%)	408,405 (90.0%)	408,502 (90.1%)	408,595 (90.1%)	408,629 (90.1%)
Dose 3+	279,023 (61.5%) 81,074 (17.9%)	280,858 (61.9%) 97,970 (21.6%)	281,726 (62.1%) 103,200 (22.8%)	282,306 (62.2%) 107,674 (23.7%)	283,133 (62.4%) 115,281 (25.4%)	, , ,	284,251 (62.7%) 121,355 (26.8%)	284,546 (62.7%) 123,227 (27.2%)	284,927 (62.8%) 126,109 (27.8%)	285,319 (62.9%) 130,280 (28.7%)	285,785 (63.0%) 135,828 (29.9%)	286,132 (63.1%) 139,758 (30.8%)	286,341 (63.1%) 141,550 (31.2%)	286,493 (63.2%) 142,547 (31.4%)	286,604 (63.2%) 143,223 (31.6%)	286,656 (63.2%) 143,538 (31.6%)
Dose 4+ Dose 5+	1,263 (0.3%)	1,702 (0.4%)	1,935 (0.4%)	2,203 (0.5%)	2,884 (0.6%)	3,356 (0.7%)	3,587 (0.8%)	10,328 (2.3%)	26,501 (5.8%)	43,165 (9.5%)	58,541 (12.9%)	67,796 (14.9%)	71,694 (15.8%)	73,752 (16.3%)	75,239 (16.6%)	76,023 (16.8%)
Dose 6+	42 (0.0%)	53 (0.0%)	1,933 (0.4%) n.p.	71 (0.0%)	91 (0.0%)	, , ,	117 (0.0%)	272 (0.1%)	696 (0.2%)	1.186 (0.3%)	1.707 (0.4%)	2.064 (0.5%)	2.268 (0.5%)	2,754 (0.6%)	4.588 (1.0%)	6,202 (1.4%)
Primary Course	7.046.793 (87.1%)	7.054.013 (87.2%)	7.058.920 (87.2%)	7.062.664 (87.3%)	7,066,841 (87.3%)	( ,	7.074.069 (87.4%)	7,076,156 (87.4%)	7.078.369 (87.5%)	7,080,386 (87.5%)	7.083.002 (87.5%)	7.085.057 (87.5%)	7.086.461 (87.6%)	7.087.646 (87.6%)	7,088,359 (87.6%)	7.088.730 (87.6%)
Dose 3+	4.342.493 (53.7%)	4.382.110 (54.1%)	4.406.224 (54.4%)	4.419.636 (54.6%)	4.436.168 (54.8%)	4.448.367 (55.0%)	4.458.233 (55.1%)	4.465.317 (55.2%)	4,473,722 (55.3%)	4.480.499 (55.4%)	4.488.689 (55.5%)	4.494.741 (55.5%)	4.498.498 (55.6%)	4.501.623 (55.6%)	4.503.512 (55.6%)	4.504.394 (55.7%)
Dose 4+	1,306,941 (16.1%)	1,517,705 (18.8%)	1,578,485 (19.5%)	1,618,832 (20.0%)	1,696,281 (21.0%)	, -, (,	1,758,004 (21.7%)	1,776,322 (21.9%)	1,807,333 (22.3%)	1,852,260 (22.9%)	1,917,448 (23.7%)	1,958,853 (24.2%)	1,977,306 (24.4%)	1,987,780 (24.6%)	1,993,996 (24.6%)	1,996,818 (24.7%)
Dose 5+	15,555 (0.2%)	21,428 (0.3%)	24,340 (0.3%)	27,749 (0.3%)	37,464 (0.5%)	44,519 (0.6%)	48,970 (0.6%)	111,733 (1.4%)	299,773 (3.7%)	508,195 (6.3%)	728,531 (9.0%)	845,027 (10.4%)	896,147 (11.1%)	924,030 (11.4%)	941,159 (11.6%)	949,280 (11.7%)
Dose 6+	593 (0.0%)	709 (0.0%)	780 (0.0%)	931 (0.0%)	1,283 (0.0%)	1,596 (0.0%)	1,785 (0.0%)	3,094 (0.0%)	7,614 (0.1%)	12,695 (0.2%)	19,232 (0.2%)	23,773 (0.3%)	26,110 (0.3%)	30,061 (0.4%)	43,582 (0.5%)	54,615 (0.7%)
Primary Course	4,340,652 (83.2%)	4,344,895 (83.3%)	4,347,737 (83.3%)	4,349,864 (83.4%)	4,352,204 (83.4%)	4,353,883 (83.4%)	4,355,907 (83.5%)	4,357,127 (83.5%)	4,358,353 (83.5%)	4,359,596 (83.6%)	4,361,112 (83.6%)	4,362,436 (83.6%)	4,363,409 (83.6%)	4,364,384 (83.6%)	4,364,893 (83.7%)	4,365,136 (83.7%)
Dose 3+	2,489,956 (47.7%)	2,511,158 (48.1%)	2,521,850 (48.3%)	2,529,447 (48.5%)	2,539,464 (48.7%)	2,546,188 (48.8%)	2,552,442 (48.9%)	2,556,749 (49.0%)	2,561,527 (49.1%)	2,565,894 (49.2%)	2,571,189 (49.3%)	2,575,302 (49.4%)	2,578,159 (49.4%)	2,580,342 (49.5%)	2,581,671 (49.5%)	2,582,267 (49.5%)
Dose 4+	804,237 (15.4%)	923,777 (17.7%)	953,766 (18.3%)	974,980 (18.7%)	1,022,073 (19.6%)	1,041,261 (20.0%)	1,051,331 (20.1%)	1,059,975 (20.3%)	1,075,279 (20.6%)	1,099,539 (21.1%)	1,133,487 (21.7%)	1,156,783 (22.2%)	1,168,009 (22.4%)	1,174,611 (22.5%)	1,177,920 (22.6%)	1,179,395 (22.6%)
Dose 5+	7,465 (0.1%)	10,372 (0.2%)	11,747 (0.2%)	13,240 (0.3%)	18,267 (0.4%)	21,221 (0.4%)	23,048 (0.4%)	58,457 (1.1%)	168,032 (3.2%)	295,208 (5.7%)	424,636 (8.1%)	496,006 (9.5%)	527,536 (10.1%)	544,124 (10.4%)	553,208 (10.6%)	557,173 (10.7%)
Dose 6+	242 (0.0%)	290 (0.0%)	316 (0.0%)	358 (0.0%)	522 (0.0%)	619 (0.0%)	682 (0.0%)	1,272 (0.0%)	3,332 (0.1%)	5,855 (0.1%)	8,778 (0.2%)	10,713 (0.2%)	11,803 (0.2%)	13,399 (0.3%)	17,902 (0.3%)	21,809 (0.4%)
Primary Course	5,824,125 (88.9%)	5,829,194 (89.0%)	5,832,320 (89.1%)	5,834,771 (89.1%)	5,837,727 (89.2%)	, ,	5,843,647 (89.2%)	5,845,421 (89.3%)	5,847,251 (89.3%)	5,849,075 (89.3%)	5,851,401 (89.4%)	5,853,293 (89.4%)	5,854,517 (89.4%)	5,855,482 (89.4%)	5,856,229 (89.4%)	5,856,641 (89.4%)
Dose 3+	3,796,264 (58.0%)	3,820,217 (58.3%)	3,832,060 (58.5%)	3,840,999 (58.7%)	3,851,310 (58.8%)	, , , ,	3,866,223 (59.0%)	3,871,563 (59.1%)	3,877,481 (59.2%)	3,882,609 (59.3%)	3,888,751 (59.4%)	3,893,459 (59.5%)	3,896,590 (59.5%)	3,899,087 (59.5%)	3,900,743 (59.6%)	3,901,604 (59.6%)
Dose 4+	1,000,685 (15.3%)	1,171,649 (17.9%)	1,220,003 (18.6%)	1,256,380 (19.2%)	1,325,271 (20.2%)	, , . , . , ,	1,378,163 (21.0%)	1,394,018 (21.3%)	1,421,024 (21.7%)	1,462,161 (22.3%)	1,524,149 (23.3%)	1,564,824 (23.9%)	1,582,612 (24.2%)	1,591,471 (24.3%)	1,596,598 (24.4%)	1,599,318 (24.4%)
Dose 5+	9,857 (0.2%)	13,546 (0.2%) 387 (0.0%)	15,360 (0.2%)	17,838 (0.3%)	24,541 (0.4%)	, , ,	32,925 (0.5%)	82,190 (1.3%)	235,030 (3.6%)	404,828 (6.2%)	591,932 (9.0%)	696,404 (10.6%)	740,889 (11.3%)	761,118 (11.6%)	773,007 (11.8%)	780,065 (11.9%)
Dose 6+	304 (0.0%)	(0.0,-)	441 (0.0%)	515 (0.0%)	733 (0.0%)	` ,	988 (0.0%)	1,920 (0.0%)	4,794 (0.1%)	8,423 (0.1%)	12,984 (0.2%)	16,352 (0.2%)	18,123 (0.3%)	21,112 (0.3%)	29,258 (0.4%)	38,066 (0.6%)
Primary Course  Dose 3+	1,542,247 (85.5%) 1.022.260 (56.7%)	1,543,884 (85.6%) 1.031.011 (57.2%)	1,544,986 (85.7%) 1.035.325 (57.4%)	1,545,902 (85.7%) 1.038.139 (57.6%)	1,546,797 (85.8%) 1.041.097 (57.7%)	, , , ,	1,548,392 (85.9%) 1.044.868 (57.9%)	1,548,893 (85.9%) 1.046.305 (58.0%)	1,549,503 (85.9%) 1.048.019 (58.1%)	1,550,005 (86.0%) 1.049.449 (58.2%)	1,550,667 (86.0%) 1.051.203 (58.3%)	1,551,163 (86.0%) 1.052.491 (58.4%)	1,551,578 (86.0%) 1.053.384 (58.4%)	1,551,861 (86.1%) 1.054.069 (58.5%)	1,552,117 (86.1%) 1.054.551 (58.5%)	1,552,254 (86.1%) 1.054,797 (58.5%)
Dose 4+	324,102 (18.0%)	370,776 (20.6%)	387,551 (21.5%)	400,919 (22.2%)	420,428 (23.3%)	427,915 (23.7%)	431,503 (23.9%)	435,574 (24.2%)	442,594 (24.5%)	452,166 (25.1%)	464,659 (25.8%)	472,901 (26.2%)	476,829 (26.4%)	479,019 (26.6%)	480.408 (26.6%)	480.964 (26.7%)
Dose 5+	2,738 (0.2%)	4,008 (0.2%)	4,715 (0.3%)	5,517 (0.3%)	7,286 (0.4%)	8,309 (0.5%)	8,868 (0.5%)	29,890 (1.7%)	87,599 (4.9%)	138,738 (7.7%)	188,770 (10.5%)	217,501 (12.1%)	231,094 (12.8%)	238,209 (13.2%)	242,645 (13.5%)	244,625 (13.6%)
Dose 6+	78 (0.0%)	94 (0.0%)	105 (0.0%)	175 (0.0%)	300 (0.0%)	343 (0.0%)	373 (0.0%)	701 (0.0%)	1,686 (0.1%)	2,734 (0.2%)	3,835 (0.2%)	4,619 (0.3%)	5,073 (0.3%)	6,078 (0.3%)	9,610 (0.5%)	12,364 (0.7%)
Primary Course	193,051 (77.5%)	193.213 (77.5%)	193,335 (77.6%)	193,452 (77.6%)	193,547 (77.7%)	,	193.665 (77.7%)	193,708 (77.7%)	193,748 (77.7%)	193,795 (77.8%)	193,856 (77.8%)	193.906 (77.8%)	193,933 (77.8%)	193,963 (77.8%)	193,974 (77.8%)	193,990 (77.8%)
Dose 3+	130,762 (52.5%)	131,687 (52.8%)	132,219 (53.1%)	132,525 (53.2%)	132,862 (53.3%)	133,094 (53.4%)	133,269 (53.5%)	133,392 (53.5%)	133,519 (53.6%)	133,607 (53.6%)	133,743 (53.7%)	133,902 (53.7%)	134,001 (53.8%)	134,080 (53.8%)	134,151 (53.8%)	134,178 (53.8%)
Dose 4+	17,881 (7.2%)	23,244 (9.3%)	24,983 (10.0%)	26,066 (10.5%)	27,817 (11.2%)	29,073 (11.7%)	29,614 (11.9%)	30,104 (12.1%)	30,682 (12.3%)	31,408 (12.6%)	32,556 (13.1%)	33,409 (13.4%)	33,970 (13.6%)	34,338 (13.8%)	34,559 (13.9%)	34,670 (13.9%)
Dose 5+	242 (0.1%)	337 (0.1%)	388 (0.2%)	437 (0.2%)	535 (0.2%)	636 (0.3%)	682 (0.3%)	1,210 (0.5%)	3,060 (1.2%)	5,119 (2.1%)	7,975 (3.2%)	9,687 (3.9%)	10,537 (4.2%)	11,033 (4.4%)	11,360 (4.6%)	11,529 (4.6%)
Dose 6+	13 (0.0%)	n.p.	n.p.	23 (0.0%)	n.p.	n.p.	n.p.	41 (0.0%)	77 (0.0%)	108 (0.0%)	160 (0.1%)	220 (0.1%)	256 (0.1%)	294 (0.1%)	373 (0.1%)	430 (0.2%)
Primary Course	497,136 (87.5%)	497,525 (87.6%)	497,673 (87.6%)	497,814 (87.7%)	497,969 (87.7%)	498,135 (87.7%)	498,291 (87.7%)	498,398 (87.8%)	498,522 (87.8%)	498,659 (87.8%)	498,829 (87.8%)	498,972 (87.9%)	499,077 (87.9%)	499,152 (87.9%)	499,202 (87.9%)	499,228 (87.9%)
Dose 3+	323,990 (57.0%)	326,426 (57.5%)	327,325 (57.6%)	327,908 (57.7%)	328,544 (57.9%)	329,114 (58.0%)	329,549 (58.0%)	329,922 (58.1%)	330,419 (58.2%)	330,991 (58.3%)	331,827 (58.4%)	332,471 (58.5%)	332,807 (58.6%)	333,049 (58.6%)	333,201 (58.7%)	333,295 (58.7%)
Dose 4+	109,822 (19.3%)	128,586 (22.6%)	133,477 (23.5%)	136,829 (24.1%)	143,238 (25.2%)	, , ,	147,759 (26.0%)	149,142 (26.3%)	151,875 (26.7%)	156,742 (27.6%)	164,751 (29.0%)	169,642 (29.9%)	171,669 (30.2%)	172,661 (30.4%)	173,215 (30.5%)	173,494 (30.5%)
Dose 5+	1,190 (0.2%)	1,807 (0.3%)	2,092 (0.4%)	2,384 (0.4%)	3,063 (0.5%)	3,620 (0.6%)	3,901 (0.7%)	10,924 (1.9%)	30,083 (5.3%)	51,335 (9.0%)	75,581 (13.3%)	88,485 (15.6%)	93,681 (16.5%)	95,939 (16.9%)	97,285 (17.1%)	98,056 (17.3%)
Dose 6+	26 (0.0%)	n.p.	38 (0.0%)	n.p.	66 (0.0%)	( /	n.p.	254 (0.0%)	699 (0.1%)	1,271 (0.2%)	1,925 (0.3%)	2,393 (0.4%)	2,602 (0.5%)	2,962 (0.5%)	4,695 (0.8%)	5,990 (1.1%)
Primary Course	2,388,325 (86.9%)	2,390,142 (86.9%)	2,391,315 (87.0%)	2,392,307 (87.0%)	2,393,242 (87.0%)	, , , ,	2,394,781 (87.1%)	2,395,226 (87.1%)	2,395,788 (87.1%)	2,396,348 (87.1%)	2,397,261 (87.2%)	2,397,826 (87.2%)	2,398,138 (87.2%)	2,398,376 (87.2%)	2,398,564 (87.2%)	2,398,669 (87.2%)
Dose 3+	1,745,192 (63.5%)	1,752,495 (63.7%)	1,756,305 (63.9%)	1,759,299 (64.0%)	1,761,976 (64.1%)	, , , ,	1,765,791 (64.2%)	1,766,962 (64.3%)	1,768,156 (64.3%)	1,769,247 (64.3%)	1,770,817 (64.4%)	1,771,977 (64.4%)	1,772,684 (64.5%)	1,773,199 (64.5%)	1,773,535 (64.5%)	1,773,703 (64.5%)
Dose 4+	412,322 (15.0%)	481,303 (17.5%)	504,094 (18.3%)	521,701 (19.0%)	548,301 (19.9%)	564,078 (20.5%)	572,055 (20.8%)	577,634 (21.0%)	584,739 (21.3%)	596,945 (21.7%)	623,816 (22.7%)	639,511 (23.3%)	644,964 (23.5%)	647,781 (23.6%)	649,362 (23.6%)	650,110 (23.6%)
Dose 5+ Dose 6+	3,021 (0.1%) 98 (0.0%)	4,402 (0.2%) 117 (0.0%)	5,221 (0.2%) 127 (0.0%)	6,176 (0.2%) 145 (0.0%)	8,707 (0.3%) 210 (0.0%)	10,484 (0.4%) 256 (0.0%)	11,589 (0.4%) 284 (0.0%)	28,749 (1.0%) 505 (0.0%)	72,031 (2.6%) 1,179 (0.0%)	137,916 (5.0%) 2,334 (0.1%)	225,232 (8.2%) 4,067 (0.1%)	267,806 (9.7%) 5,178 (0.2%)	284,147 (10.3%) 5,713 (0.2%)	292,508 (10.6%) 6,501 (0.2%)	297,166 (10.8%) 8,340 (0.3%)	299,434 (10.9%) 10,227 (0.4%)
* Other ATAGI changes to recon	, ,		, ,	, ,	. ,	, ,	` ,	505 (0.0%)	1,179 (0.0%)	2,334 (U.1%)	4,007 (0.1%)	5,1/8 (U.Z%)	5,/15 (U.2%)	0,301 (0.2%)	6,340 (0.3%)	10,227 (0.4%)

<sup>\*</sup> Other ATAGI changes to recommendations since the commencement of the Program in 2021 will also impact the ability to compare dose administrations over the time period

Data sourced from the Australian Immunisation Register as at 11:59pm 18/10/2023. Extracted 23/10/2023

## **Specifics**

Primary Course: Counts the number of people who have commenced a primary course or received at least one dose of any COVID-19 vaccination. Individuals may require multiple doses to complete a primary course depending on vaccine type received and individual circumstances such as severe immunocompromise.

Low Population Supression: Cells have been suppressed with < 10 when the total population in the cell has a value greater than 0 or less than 10.

Consequential Suppression: For general population tables, cells have been suppressed with n.p. (n.p. = not provided) where needed to prevent reverse engineering of <10 values, or where relative difference between included values is less than 10. These values are usually larger than 10.

Cumulative Population: Count values included represent total cumulative number of individuals vaccinated up to the end of the month as stated.

Back Dated Data: General population records are reported as of encounter date not date of first reporting. This will vary significantly from other published data due to back dated records being recorded at a later date.

Individual Dose Status: Includes all individuals in dose number higher categories. For example, Dose 3+ includes all individuals who have had dose 4 or higher. As a result state totals by dose number are not additive.

**Doses Administered:** Includes all doses administered to individuals regardless of dose sequence number.

## Caveats

Encounter Month: Is based on the date of physical administration as reported in AIR, not the date of first reporting which may differ from other published figures.

Current Age: Is determined based on an individuals age as of 19 October 2023, individuals may have received their doses while in younger age cohorts.

Medicare Address State: Is based on the patients best known address as of 19 October 2023. Individuals may have received their dose in different states than they currently reside.

End Dated Records: Due to the time series nature of this extract, end dated individuals are included even if they have subsequently died or permanently emigrated from Australia. These individuals are usually removed from point-in-time person level reporting.

Incomplete Month: October 2023 data includes data up to 18 October 2023 and is not a complete month.